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Abstract: Doxorubicin (DOX) is an anticancer anthracycline that presents a dose-dependent and cu-
mulative cardiotoxicity as one of the most serious side effects. Several hypotheses have been advanced to
explain DOX cardiac side effects, which culminate in the development of life-threatening cardiomyopa-
thy. One of the most studied mechanisms involves the activation of DOX molecule into a more reactive
semiquinone by mitochondrial Complex I, resulting in increased oxidative stress. The present review de-
scribes and critically discusses what is known about some of the potential mechanisms of DOX-induced
cardiotoxicity including mitochondrial oxidative damage and loss of cardiomyocytes. We also discuss al-
terations of mitochondrial metabolism and the unique characteristics of DOX delayed toxicity, which can
also interfere on how the cardiac muscle handles a “second-hit stress.” We also present pharmaceutical
and nonpharmaceutical approaches that may decrease DOX cardiac alterations in animal models and
humans and discuss the limitations of each strategy. C© 2013 Wiley Periodicals, Inc. Med. Res. Rev., 34, No. 1,
106–135, 2014
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1. INTRODUCTION: DOXORUBICIN AS A CARDIOTOXIC ANTICANCER AGENT
Doxorubicin (DOX) is an antitumor anthracycline antibiotic, isolated from colonies of Strep-
tomyces peucetius caesius in 1967.1,2 DOX is one of the most-used antitumor anthracyclines,
being highly active against an extensive variety of neoplastic diseases, even at lower doses.2
The first in vivo studies performed with DOX in cancer animal models demonstrated inhi-
bition of neoplastic proliferation and increased animal survival.1 DOX efficacy was tested in
humans on different types of malignancies, such as leukemias, lymphomas, and solid tumors,
Correspondence to: Paulo J. Oliveira, PhD, Center for Neuroscience and Cell Biology, Largo Marques de Pombal,
University of Coimbra, 3004–517 Coimbra, Portugal, E-mail: pauloliv@ci.uc.pt
Medicinal Research Reviews, 34, No. 1, 106–135, 2014
C© 2013 Wiley Periodicals, Inc.
DOXORUBICIN-INDUCED CARDIOTOXICITY  107
including gynecological, urogenital, endocrine, stomach cancer, as well as Ewing and Kaposi’s
sarcomas.2,3 The mechanisms of action of DOX in tumor cells essentially involve interaction
with the nucleus, mitochondria, and biological membranes, although some of these targets are
also affected in non-target cells as well. The main mechanisms that have been suggested for
DOX anticancer effects include: (1) DOX intercalation into DNA, leading to inhibition of pro-
tein synthesis and DNA replication; (2) generation of reactive oxygen species (ROS), leading to
DNA damage and/or lipid peroxidation; (3) DNA cross-linking, binding, and alkylation; (4)
interference with DNA unwinding or DNA strand separation and helicase activity; (5) direct
membrane effect with disruption of the bilayer structure; and (6) initiation of DNA damage
via inhibition of topoisomerase II.4,5
During preliminary toxicity tests in patients, several side effects were detected, including
nausea, vomiting, and fever.2 Furthermore, a significant incidence of cardiovascular side effects
namely hypotension, tachycardia, arrhythmias, and ultimately congestive heart failure were
also described.6 Acute DOX side effects, including pericarditis-myocarditis or arrhythmias,
are generally reversible and clinically manageable.7,8 However, the mortality of patients that
develop congestive heart failure afterDOX chronic treatment can be as high as 50%,9 increasing
significantly when cumulative doses higher than 500 mg/m2.6
The objective of this review is to critically evaluate old and recent knowledge regarding
DOX-induced cardiomyopathy, identifying primary molecular targets, which lead to a dete-
rioration of cardiac performance, resulting in decreased resistance to “second-hit stresses”
and developing toward cardiomyopathy. We also explore some of the therapeutics aimed at
decreasing DOX cardiotoxicity, pointing out defects and virtues of each strategy.
2. DOX CARDIOTOXICITY—FROM MOLECULAR EVENTS TO CARDIOMYOPATHY
A. DOX-Induced Cardiac Toxicity—From Acute to Chronic to Delayed
Acute DOX injury occurs rapidly after a single dose or course of therapy, with clinical man-
ifestations occurring from a few minutes to a week of treatment.10 These manifestations may
include transient electrophysiological abnormalities, observed in 20–30% of patients, which
comprise nonspecific ST- and T-wave changes, T-wave flattening, decreased QRS voltage and
prolongation of QT interval, sinus tachycardia, and supraventricular arrhythmias.6 Although
rare, pericarditis or myocarditis syndrome and acute left ventricular failure have been ob-
served in some fatal cases.11–13 On the other hand, chronic side effects are more serious, ir-
reversible, and involve the development of cardiomyopathy and ultimately congestive heart
failure.14,15
The prevalence of left ventricular contractile dysfunction in patients with a cumulative
DOX dose of approximately 430–600 mg/m2 is about 50–60%, in which a significant incidence
of cardiomyopathic episodes is observed. The incidence of heart failure is nearly 2% with a
cumulative dose of 300 mg/m2 but rapidly increases to 20% at cumulative doses in excess of
more than 550 mg/m2.16–20
Early-onset, chronic, progressive cardiotoxicity usually occurs within a year of treat-
ment, persisting or progressing even after discontinuation of anthracycline therapy, leading
to chronic dilated cardiomyopathy in adult patients and to restrictive cardiomyopathy in pedi-
atric patients.16,21 DOX-induced left ventricular dysfunction is generally insidious in onset and
progressive in nature with cumulative dosage.18,19 If treatment with DOX is continued after the
onset of subclinical left ventricular dysfunction, a rapid decline in left ventricular function and
heart failure occurs.20 On the other hand, late-onset progressive cardiotoxicity results in ven-
tricular dysfunction, heart failure, and arrhythmias years or even decades after chemotherapy
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occurred, suggesting the need for a continuous follow-up of the cardiac status of patients who
received anthracyclines.21,22
B. Risk Factors
A number of risk factors contributes to DOX-induced cardiotoxicity, including the total cu-
mulative dose, total dose administered during a day or a course of treatment, rate and schedule
of administration, mediastinal radiation, age, gender, concurrent administration of cardiotoxic
agents, combined therapy, prior anthracycline chemotherapy, history of preexisting cardiovas-
cular disorders, hypertension, liver disease, and electrolyte imbalances such as hypokalaemia
and hypomagnesaemia.13,17,23,24 Age seems to be the most significant risk factor since children,
adolescents, and elderly patients are the most susceptible to the cardiotoxic effects of DOX
chemotherapy.25–27 Particularly in children, the reason may be related to specific effects on
pluripotent stem cells in postnatal hearts, disturbing their ability to differentiate to functional
cardiomyocytes. Similarly to other undifferentiated cells, cardiac stem cells can be more sus-
ceptible to DOX and their loss will limit the regenerative capacity of heart.28 It is possible that
DOX-induced loss of cardiomyocytes together with an early damage to cardiac stem cells in
pediatric patients can result in a permanent compromised cardiac function among long-term
cancer survivors. Loss of myocytes and impaired cardiac growth results in inadequate left
ventricular mass and may result in the development of cardiomyopathy a year or more after
cessation of chemotherapy.29 Nevertheless, cardiomyocyte atrophy and myofiber disarray may
also contribute to cardiac dysfunction observed in DOX-treated juvenile patients or animal
models.30 Regarding older age groups, aging impacts DOX pharmacokinetics, which is particu-
larly evident in the heart.31,32 Age is also highly correlated with drug clearance, which is reduced
in the heart tissue of elderly patients andmay contribute to DOX-induced cardiotoxicity.33 This
is critically important as postmortem analysis of patients who were treated with DOX showed
high accumulation of this drug in the cardiac tissue versus other muscle tissues.34 Age-related
DOX cardiotoxicity was also attributed to the decline in regional blood flow with age that may
be responsible for the altered DOX concentration-time course in plasma and heart tissue.33
Taking into account the diverse risk factors, it is important that each patient treated with
DOX undergoes an assessment of baseline cardiac function before chemotherapy, a regular
monitoring during treatment and a close lifelong follow-up in an attempt to minimize the risk
of development of irreversible cardiotoxicity.19,35
DOX-induced cardiotoxicity often results in enlarged hearts, with dilation of all chambers
and mural thrombi, commonly observed in both ventricles.36 Also, multifocal areas of irregular
and interstitial fibrosis and spotted cardiomyocytes with vacuolization were already detected.36
Myofibrillar loss and vacuolar degeneration have been two classical ultrastructural features of
DOX cardiotoxicity.37 Despite the large array of clinical outcomes resulting fromDOX toxicity,
it has been suggested that a specific, progressive, and subclinical anthracycline injury to the
human heart cannot be consistently detected by conventional tests.37
C. The Beginning of the End: DOX-Induced Cardiac Ultrastructural Alterations
At a cellular and molecular level, DOX cardiotoxicity has been associated with ultrastruc-
tural changes in cardiomyocytes, namely cytoplasmic vacuolization involving distention of
T-tubules and sarcoplasmic reticulum; myofibrillar disorganization and loss; mitochondrial
alterations including swelling35,38–40 and cristae disruption41; increased number of lysosomes42;
and clumping of chromatin and nucleoli shrinkage along with segregation of granular and fib-
rillar components.43 DOX disturbs the cellular cytoskeleton and microtubular polymerization,
as observed by reduced expression of α-actin, myosin light and heavy chains, tropomyosin,
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troponin I, troponin C, and desmin.36,43–45 DOX treatment also affects adhesion proteins, such
as matrix metalloproteinaseMMP-2/MMP-9 gene expression,46 resulting in cell detachment.47
Generalmitochondrial and fibrilar disorganizationwas also detected in human samples.48 Most
of these effects were replicated in vitro; DOX toxicity on H9c2 cardiomyoblasts includes mito-
chondrial depolarization and fragmentation and disorganization of themitochondrial network,
structure, as well as cytoskeleton disruption43; however, supraclinical concentrations of DOX
affect mitochondria more drastically, which is reflected by mitochondrial swelling and loss of
mitochondrial cristae in the same model.43 DOX toxicity in mitochondria has also been ob-
served in other tissues including brain,49 lung,50 and liver,51,52 although not as extensively as in
the heart.
D. The Beginning of the End: Is DOX-Induced Oxidative Stress in Cardiac Mitochondria the
Culprit?
From a mechanistically point of view, DOX-induced cardiotoxicity has been attributed to a
number of causes, including increased oxidative stress, direct inhibition of key transporters
involved in ion homeostasis (such as Na+-K+ ATPase and Ca2+ ATPase), which results in al-
terations in cellular calcium homeostasis, increased cytosolic iron accumulation, mitochondrial
failure, inhibition of nucleic acid and protein synthesis, release of vasoactive amines, changes
in adrenergic function, lysosomal alterations, and apoptosis.35,49,53
The long list of mechanisms that have been proposed to explain the development of DOX-
induced cardiomyopathy demonstrates that the cause is probably multifactorial and complex,
but most of these alterations may be attributed to free oxygen radicals production, mitochon-
drial and bioenergetic failure, which may ultimately develop in apoptosis35 (Fig. 1).
The heart is particularly susceptible to DOX-induced oxidative damage because of the
large density/volume of mitochondria, which are both important sources and targets of ROS
(see below), their elevated rate of oxygen consumption, and the lower amount of antioxidant
defenses compared with other tissues, such as the liver.41,54,55 In fact, cardiomyocytes express
low levels of catalase,56 while selenium-dependent GSH-peroxidase-1 is readily inactivated after
exposure to DOX,56 which also decreases cytosolic Cu-Zn superoxide dismutase.57 A decrease
in the content/activity of antioxidant enzymes may represent a common response to DOX
treatment,36 at least in a specific time point. But what is the relationship between DOX and
oxidative stress?
One major hypothesis for DOX toxicity is based on the generation of oxidative stress
through interaction with iron and oxygen. With an univalent redox potential of approximately
-320 mV, DOX is a favorable substrate for reduction by a number of oxidoreductases within
the cell, including NADPH-dependent cytochrome P450 reductase,58 NADH-dehydrogenase
of mitochondrial complex I,59,60 and assorted soluble oxidoreductases present in the cyto-
plasm, including xanthine oxidase.61 DOX can be reduced by the eNOS reductase domain,
enhancing superoxide formation.62 Also, it was reported that the Km for the reduction of
DOX to a semiquinone free radical by eNOS is ten- to 100-fold lower than the one reported
to cytochrome P450 reductase and NADH dehydrogenase.62 As the cardiac tissue has a high
number of mitochondria per cell (up to 35% of the cell volume) when compared with other
tissues, it is considered that the main enzyme involved in DOX redox cycling is complex I
(NADH:ubiquinone oxidoreductase).18 Specifically, DOX is reduced by complex I, forming a
highly reactive semiquinone, initiating a redox cycle after reacting with oxygen and releasing
ROS in the process (Fig. 2).59
DOX also coordinates with free transitional metals, such as iron, to form metal coordina-
tion complexes and stimulate production of partially reduced forms of oxygen.63 DOX-induced
oxygen-free radicals can damage phospholipids in biological membranes, increasing the cell
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Figure 1. Most consensual model for DOX-induced cardiotoxicity. Data suggest that a large component of DOX-
induced cardiotoxicity is mediated by a redox cycle on mitochondrial complex I. Increased ROS generation by
DOX redox cycle has several negative consequences, such as mitochondrial transmembrane potential (m)
disruption, MPT pore formation, ATP depletion, and peroxidation of cellular membranes. Marked mitochondrial
morphological disturbances induced by DOX include cristae disruption, matrix disorganization, and mitochon-
drial fragmentation. MPT pore-induced outer membrane rupture due to osmotic swelling or permeabilization of
the mitochondrial outer membrane mediated by proapoptotic proteins including BAX can lead to the release of
cyt c and AIF. DOX also interferes with topoisomerase II, inhibiting DNA replication and preventing the repair
of damage DNA strands. Finally, persistent downregulation of gene expression can be another consequence
of DOX toxicity. All of these events may lead to cell death. DOX, doxorubicin; Casp, caspase; m, mitochon-
drial transmembrane potential; ROS, reactive oxygen species; MPT, mitochondrial permeability transition; Cyt c,
cytochrome c; AIF, apoptosis-inducing factor; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein
kinase; ATP, adenosine triphosphate.
membrane permeability and inactivating membrane receptors and other enzymes.64,65 DOX
also presents a strong affinity for cardiolipin,66,67 one of the most abundant phospholipids in
the inner mitochondrial membrane (IMM) and which is required for the activity of respiratory
chain enzymes such as cytochrome c oxidase and NADH cytochrome c oxidoreductase.68 The
formation of drug–lipid complexes leads to an inhibition of oxidative phosphorylation because
cardiolipin can no longer act as cofactor for mitochondrial enzymes.69 Binding of DOX to car-
diolipin suggests a strong affinity for mitochondrial membranes. It remains to be determined
whether this contributes to a buildup of a DOX gradient across mitochondrial membranes. In
other words, it is still unclear the percentage of total DOX which crosses the IMM and gets
reduced by complex I in the matrix side.
Since evidences point out to a preferential interaction of DOX with cardiac mitochondria,
it is not surprising that several mitochondrial alterations including stimulation of respiratory
state 4 and decrease in respiratory state 3, as well as a decrease in the respiratory control ratio,
have been measured in different models.38,52,70–72 DOX-increased ROS generation resulted in
the oxidation of lipids, proteins, and signaling molecules.73–75 A decrease in mitochondrial
membrane potential has also been described.75
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Figure 2. Redox cycling of DOX. Univalent reduction (e−) of DOX (A) leads to the formation of a semiquinone
radical (B), which can auto-oxidize in the presence of oxygen, generating superoxide anions, reverting to the
parent compound.
In several in vitro and in vivo models, one particular aspect of DOX toxicity is a loss of
mitochondrial calcium loading capacity.38,51,52,70, 71 Cardiac mitochondria isolated fromDOX-
treated rats do not accumulate the same amount of calcium as their control counterparts. It
was demonstrated that the loss of calcium loading capacity was due to increased induction of
the mitochondrial permeability transition (MPT) pore (Fig. 3),51,76 which is a deleterious phe-
nomenon for mitochondria and cells, and which may initiate cell death induction.77 Oxidative
stress, calcium overload, or irreversible mitochondrial depolarization result in MPT induction,
and which results in increased permeability of the IMM, leading to the opening of nonselective
protein pores, which allows the passage of smaller molecules below 1.5 kDa.78
Mitochondrial permeability transition pore opening leads to mitochondrial osmotic
swelling and structural damage to mitochondria. The exact molecular nature of MPT is still
a matter of debate. Although several authors initially supported the idea that the MPT pore
was formed by the voltage-dependent anion channel (VDAC), adenine nucleotide translocase
(ANT), and cyclophilinD (CypD, also called Cyp F), it has become clear that CypD is the only
essential component of theMPT pore.79–81 Work performed in knockout (KO) animals demon-
strated that mitochondria from ANT- and VDAC-KO animals still undergo the MPT.80,82–84
Recent ideas suggest that the phosphate carrier (PiC) is instead the better candidate for theMTP
pore structural component.80,85–87 Several proteins can regulate theMPT, including creatine ki-
nases (CK), hexokinase, Bcl-2 family proteins, and peripheral-type benzodiazepine receptor.88
The opening of MPT pore can trigger the release of proapoptotic proteins such as cytochrome
c or SMAC/DIABLO due to rupture of the outer mitochondrial membrane or due to the
recruitment of proapoptotic proteins.80
Increased MPT pore opening in DOX-treated animals can be dependent on the higher
basal oxidation of specific thiol residues in mitochondrial proteins.89 DOX-induced cardiac
MPT pore is prevented by the use of several specific inhibitors such as ATP or Cyclosporin
A (CsA).90 Alterations induced by DOX on the ANT can also lead to altered opening of the
MPT pore through an apparent regulatory mode and to decreased oxidative phosphorylation
due to its ADP/ATP shuttling activity.70,91,92 Inhibition of the ANT in its adenine nucleotide
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Figure 3. Mitochondrial permeability transition (MPT) pore structure. It was recently proposed that the MPT pore
is composed/regulated by the matricial protein cyclophilin D (CypD) and by the mitochondrial phosphate carrier
(PiC), with the adenine nucleotide translocator (ANT) probably having a regulatory role. In addition, the MPT pore
can be regulated by other components, such as hexokinase (HK), creatine kinase (CK), and peripheral-type
benzodiazepine receptors (PBR). Both antiapoptotic and proapoptotic members of the Bcl-2 family modulate the
activity of MPT pore (antiapoptotic members of the Bcl-2 family, including Bcl-2 and Bcl-XL, inhibit pore opening
while proapoptotic Bcl-2 family members, such as Bax, Bak, and Bid, can induce MPT pore opening). Also,
MPT pore opening can be inhibited by CypD ligands, such as cyclosporin A (CsA). The opening of MPT pore
leads to a collapse of transmembrane mitochondrial transmembrane potential (m) and favors the release of
apoptogenic proteins, such as cytochrome c (Cyt c) and SMAC/DIABLO (second mitochondria-derived activator
of caspases/direct IAP binding protein with low PI).
translocator function can result in an inhibition of respiratory state 3, which is observed in
several in vitromodels.93 The fact that loss of calcium loading capacity was observed in somany
biological models for DOX-induced toxicity led to the cunning idea that this is in fact an early
and sensitive marker for DOX-induced cardiotoxicity.38 Nevertheless, evidence also exists for
a primary mitochondrial membrane depolarization, which precedes a matrix calcium overload
and increased ROS production.75 Whether the primary event is mitochondrial depolarization
or the loss of calcium loading capacity caused by thiol oxidation remains to be confirmed.
Deleterious alterations in cardiac mitochondrial function, including decreased calcium
loading capacity and gene expression profile have been demonstrated in rodent models to be
irreversible (at least until the studied time point),76,94,95 which again supports the notion that
DOX toxicity in the myocardium is cumulative and irreversible in nature.
DOXalso damagesmitochondrialDNA (mtDNA),96 by forming adducts with that circular
genome and therefore disturbing the process of synthesis of mitochondrial machinery.97–99 The
oxidation of mtDNA100,101 can result in a defective respiratory chain, which will then be unable
to respond to high energy demands and produce a higher leakage of electrons to molecular
oxygen, increasing ROS production, which then perpetuates the mitochondrial bioenergetic
failure. In fact, damage to mtDNA, including loss of mtDNA copies, which closely follows
alterations in the respiratory chain, has been described as preceding the accumulation of calcium
deposits, suggesting that an early bioenergetic failure may contribute to calcium overload in the
matrix.102 What is critically important is that mtDNA alterations, including rearrangements,
deletions, and decreased copy number, were found in the hearts, but not skeletal muscle, not
only from animal models,103 but also from deceased patients after DOX treatment.48 This
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suggests that mtDNA alterations may accumulate with time, even in the absence of treatment,
leading to a defective respiratory chain, which, by its turn, would generate more ROS and
contribute to increase mtDNA damage. This appears a great explanation for the persistent and
cumulative nature of DOX cardiotoxicity, which suggests a positive feedback loop between
mtDNA alterations, respiratory chain deficiencies, both progressing with time, and later matrix
calcium accumulation. Once a low bioenergetic threshold is achieved, cardiac mitochondria
lose the ability to respond to different stresses by increasing biogenesis, resulting in cardiac
failure. In this context, congestive failure would appear decades after treatment due to the
progressive nature of mtDNA degeneration. This question should be better confirmed in future
studies as well as why other tissues are not so affected.
The above described strongly suggests that DOX-induced oxidative stress can an impor-
tant factor in the development of cardiac toxicity. If this is true, then a prophylactic measure to
stop cardiac deterioration would involve the use of antioxidants. In vitro data indicate that an-
tioxidants are marginally effective to counteract DOX-induced toxicity on cardiomyoblasts104;
other data confirm that results with antioxidants yield mixed results.105–108 One of the first
antioxidants tested against DOX cardiotoxicity was vitamin E.55 A bolus injection of vitamin
E before DOX administration prevented the typical cardiac alterations in mice.109 Other studies
showed conflicting results regarding the efficiency of vitaminE and further research showed that
vitamin E was cardioprotective only against acute cardiotoxicity resulting from anthracycline
chemotherapy but offered no protection against the development of chronic cardiomyopathy.110
Berthiaume et al.111 showed that vitamin E-succinate prevented cardiac oxidative stress but not
mitochondrial alterations. Interestingly, vitamin E-succinate112 and vitamin E113 increased the
anticancer effects of DOX in tumor cell lines.
Carvedilol, a clinically approved drug that acts as a nonselective β-adrenergic blocker
agent and also blocks α1-receptor with vasodilatory properties, has also been described to
have potent antioxidant activity.52,108 In different models, carvedilol prevented DOX-induced
left ventricular dysfunction52,108,114,115 and DOX-induced apoptosis of cardiac cells, as well
as hydrogen peroxide generation.108 Comparing effects of carvedilol with atenolol, another β-
adrenergic blocker agent lacking antioxidant activity, it was concluded that carvedilol protective
effects against DOX toxicity resulted predominantly from the antioxidant effect and not from
the β-adrenergic blocker activity, since atenolol did not prevent or inhibit DOX-induced ROS
production and cardiac apoptosis.108,114,116 Nevertheless, it may be speculated that the cardiac
sparing effect of carvedilol, resulting from β-adrenergic blocking activity, may actually decrease
some of the metabolic burden placed on already damaged mitochondria, thus synergizing
with the antioxidant effect. Several other studies demonstrated that carvedilol was effective in
decreasing cardiac mitochondrial damage induced in a subchronic model for DOX toxicity,
including preventing the loss of mitochondrial calcium loading capacity.52,116 Interestingly,
carvedilol was shown to inhibit a hypothetical cardiac NADH dehydrogenase in the outer
leaflet of the IMM,117 which was proposed to be another possible mediator of DOX redox cycle
in the heart.118
However, further studies are necessary to verify if the protective action of carvedilol may
be useful not only in the prevention of DOX-induced cardiotoxicity, but also to confirm that
carvedilol does not interfere with the DOX antitumor activity.108,114,119,120
Despite the positive impact of some antioxidants against DOX cardiotoxicity, the truth
is that no one has demonstrated without doubt that macromolecular damage resulting from
DOX-generatedmitochondrial oxidative stress is the culprit for the cardiomyopathy that results
from treatment or if instead mitochondrial oxidative stress only has an important role in the
initial acute toxicity observed.
Dexrazoxane is an intracellularly activated chelating agent with structural similarity to
EDTA and was found to have cardioprotective effects.121 Dexrazoxane prevents functional
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damage of cardiac mitochondria initiated and perpetued by ROS, which leads to a reduction of
the incidence of DOX-induced cardiomyopathy in humans and animal models.122–124 Despite
the advantages of using dexrazoxane against DOX toxicity, this cannot be seen as the proof
that oxidative stress is indeed the main culprit of DOX cardiotoxicity. In fact, equally or more
potent iron chelators such as desferrioxamine125 or deferasirox,126 have failed to afford the same
degree of protection. This may imply that iron has no role in oxidative stress-mediated DOX
toxicity, as previously suggested127 or that indeed oxidative stress has a minor role in the entire
process of DOX cardiac toxicity. Also, patients treated with dexrazoxane may have a lower
tumor response rate.128,129 In one clinical trial, patients treated with dexrazoxane presented
lower response rates (48% vs. 63%) and earlier disease progression compared with patients
receiving placebo.130
Interestingly, a recent paper confirms that global oxidative stress may not be amajor execu-
tion step in the development of anthracycline-induced cardiomyopathy; instead, it is proposed
that anthracyclines disturbmitochondrial biogenesis in response to energy deficits.131 Although
this work has been performed with daunorubicin and not with DOX, we may speculate that
a similar result may be obtained with the latter. Still, positive results have been obtained in
animal models overexpressing antioxidant enzymes including metallothionein,132 glutathione
peroxidase,133 and catalase.134 Although the disperse datamay appear difficult to conciliate, one
possibility is DOX toxicity results in localized oxidative stress, which, despite not causing ma-
jor macromolecular damage, disturbs the redox equilibrium in different cellular compartments
during and after DOX treatment. This localized oxidative stress would interfere with compart-
mentalized cell signaling andwith different redox pairsGSH/GSSGand cysteine/cystine.135,136
Differences in the efficacy of iron chelators or antioxidants may be explained by their different
intracellular localization/accumulation or even by the fact that antioxidants can disturb an
otherwise normal redox balance in specific cell compartments.137 This would result in an ap-
parent lack of protective effect against DOX cardiotoxicity. If this hypothesis is confirmed, the
development of novel mitochondrial-directed antioxidants/iron chelators could help improv-
ing DOX phenotype. One example is MitoQ, which prevented inactivation of mitochondrial
complex IV by DOX.138
Despite the promising results of multiple antioxidants, a background problem remains:
obvious protection against DOX cardiotoxicity observed in animal models rarely translates
into a similar protection in humans. Different drug distribution, metabolism and clearance,
dissimilar regulation of redox systems at the genetic level or even distinct cardiac metabolism
may all be the genesis of interspecies differences.
E. The Beginning of the End: Does DOX-Induced Loss of Cardiac Cells Contribute to
Cardiomyopathy?
Enhanced MPT pore induction resulting from DOX treatment can result in cell death.139,140
In fact, a rapidly expanding body of evidence supports the concept that both endothelial cell
and cardiomyocyte apoptosis and necrosis are involved in DOX-induced toxicity.141,142 The
molecular mechanisms underlying DOX-induced cardiomyocyte death comprise the excess
generation of ROS108,139 and other ROS-independent mechanisms, including the generation
and accumulation of ceramide143 or priming of Fas-mediated apoptosis.144
DNA damage and signaling pathways involving the tumor suppressor p53 and mitochon-
dria can also be involved in DOX-induced cardiac cell death.104,145 DOX not only induces
DNA damage and oxidative mitochondrial damage, but also induces nuclear translocation
of p53.88 Mitochondrial dysfunction in DOX-treated H9c2 cardiomyoblasts was concluded
to be secondary to p53 activation.104 Upon activation, p53 induces the expression of genes
associated with cell arrest, DNA repair, and apoptosis.88 Additionally, DOX activation of
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mitochondrial p5388 can lead to HIF-1 inhibition,146 and can promote the decrease of heart
mass via p53-dependent inhibition of mTOR signaling.145 Moreover, DNA lesions induced
by ROS or directly by DOX interaction increase phosphorylation of p53, upregulate its
downstream genes such as Bax104,140 and activate JNK and p38 MAPK pathways to induce
apoptosis.147 Confirming the involvement of the axis p53-Bax, the p53 inhibitor pifithrin-α de-
creases Bax expression and effectively inhibits DOX-induced apoptosis in H9c2 cells, neonatal
rat cardiomyocytes, and mouse hearts.88,148
An early event also observed in DOX cardiotoxicity is GATA-4 depletion, which also
leads to cardiomyocyte apoptosis.149 GATA-4 is a transcriptional factor critical in heart de-
velopment that regulates the apoptotic pathway by activating the antiapoptotic gene Bcl-XL,
thus preserving mitochondrial function and integrity.140 DOX also inhibits AKT phospho-
rylation, increasing active GSK3β, a negative regulator of GATA-4 in the nucleus.150 Also,
dephosphorylation of AKT and Bad can activate caspase-3, inducing internucleosomal DNA
damage.151
Cardiomyocyte apoptosis and consequent cell loss may be a mechanism by which DOX
causes a deterioration of cardiac function, as described in different systems.152 The evidence
supports that DOX activates apoptotic signaling through multiple mechanisms, which appar-
ently include mitochondria as initiators153 or at least magnifiers of the apoptotic signaling.
Can we inhibit apoptotic signaling to decrease DOX toxicity in the heart? As with antioxi-
dants, the data are confusing and often yields a mixed message. For example, overexpression
of the antiapoptotic protein Bcl-xL in neonatal rat cardiomyocytes decreased apoptosis but
failed to prevent downregulation of gene expression and ROS generation.154 To complicate
things further, DOX-induced cardiac cell death may also occur through caspase-independent
pathways,155 which leaves no space for the effective use of caspase inhibitors. Targeting mi-
tochondrial dysfunction to prevent apoptosis may also prove of limited value since apoptotic
signaling originating from other organelles was also found to be important in the context of
DOX cardiotoxicity. One of those organelles was shown to be the sarcoplasmic reticulum,
leading to activation of caspase 12.156 As described above, p53 signaling may be also an im-
portant drug target to prevent DOX cardiotoxicity.157 Again, this may also prove of limited
value as ablation of p53 via conditional KO was not enough to prevent DOX-induced fibrosis
and cytoskeletal alterations.158 Results showing that the p53 inhibitor pifithrin-α may have
multiple actions, including decreased expression of different caspases159 increases the suspicion
that some of the reported protective effects against DOX cardiotoxicity104,148 may be, in part,
p53 independent.
One important drawback is that the appearance of apoptotic/necrotic cardiomyocytes, as
characterized from a morphological point of view, is not a generalized event, at least when
detected in postmortem analyses of the cardiac tissue in patients.160 It may be also possible that
the peak of cardiomyocyte apoptosis may occur still during the treatment,161 and that loss of
cardiomyocytes or other cardiac cells may be compensated by increased fibrosis,162,163 leading
to an underestimation of apoptotic cardiomyocyes during post-mortem analysis. Also, the
notion that DOXmay cause senescence in cardiomyocytes, as opposed to apoptosis,164,165 adds
another layer of complexity. This new view means that DOX may trigger aging mechanisms in
the heart that may, or not, lead to the triggering of apoptotic or even autophagic166,167 signaling
mechanisms. Another problem is that avoiding apoptotic signaling in the cardiac tissue may
also result in exactly the same effect in a cancer cell, which was obviously the first target for
DOX. Interestingly, pifithrin-α increased cell death in neoplastic mouse JB6 cells by increasing
p53-mediated apoptosis.168 This suggests that this compound, regardless of its real selectivity
against p53, may contribute to reduce DOX-induced cardiac damage, and at the same time
induce death of some tumor types.
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F. Progression of Evil: DOX-Induced Metabolic Remodeling in the Heart
The progressive degeneration of mitochondrial bioenergetics during DOX treatment may cause
cardiac bioenergetic disruption, which may result in cardiac depression. In fact, the ATP or
phosphocreatine content of hearts from rats chronically treated with DOX is lower, imply-
ing decreased bioenergetic capacity.39 Metabolic readjustments are thus necessary to support
myocyte vital functions.
Effects on the global cardiac energetic network or on its individual components have
been studied in different in vitro and in vivo models for DOX-induced cardiotoxicity.93,169
The impact of DOX on global cardiac metabolism is demonstrated by the fact that DOX
not only diminishes overall mitochondrial ATP production, but leads to a rather specific
early impairment of CK isoenzymes, including mitochondrial CK isoenzymes (MtCK) and
AMPK.170,171 Compromised MtCK leads to impairment of energy channeling and signaling
between mitochondria and the cytosol and interferes with mitochondrial respiration.170,171
Inhibition of AMPK, a highly susceptible target of DOX-induced damage in the heart, blocks
mitochondrial import and inhibits the β-oxidation of fatty acids.170 Also, impaired AMPK
signaling reduces the capacity of the cell to initiate a compensatory increase in glycolytic rate
and to stimulate glucose uptake.170,172 Glycolytic enzymeshavebeen shown tobe associatedwith
sarcolemmal and sarcoplasmic reticular membranes and functionally coupled to ion transport
pathways, including calcium channels173 or the sodium/proton exchanger.174 Alterations in
glycolytic fluxes may interfere with ion transport and progressively lead to depression of cardiac
excitability.
Also, impairment of carnitine palmitoyl transferase I (CPT I) and/or depletion of its
substrate L-carnitine was observed during DOX cardiotoxicity.175,176 Since long-chain fatty
acid β-oxidation is inhibited by DOX,177 an increase of total cholesterol, triglycerides and LDL
cholesterol in the serum can be a consequence, described already in animal models.34,72 Both
glucose utilization and β-oxidation of long-chain fatty acids are impaired in DOX-induced
cardiomyopathy,36,177,178 which taken to the extreme may imply a general breakdown of energy
metabolism after DOX treatment.
Interestingly, a link between general oxidative stress and metabolic responses was already
proposed. Following 1 hour of DOX treatment, lipid peroxidation increased and caused an
adaptive response resulting in an increased glucose uptake that is manifested by an increase
in GLUT1 protein, presumably to restore cellular energy, establishing a relationship between
DOX-induced lipid peroxidation and acute alterations in glucose transport.178 Early responses
such as the induction of glycolytic and Krebs cycle genes179 may be an adaptation response to a
general bioenergetic breakdown, although a metabolic switch from oxidative phosphorylation
to glycolysis can only provide a short-term solution (and, as described above, the increase in
glycolytic fluxes is limited due to DOX off-target toxicity). An increase of lactate production,
a subproduct of glycolysis and a likely signal of decreased mitochondrial function and upreg-
ulated glycolysis, was previously described after DOX treatment.177 Through nuclear magnetic
resonance analysis of intracellular metabolites, myocardial levels of acetate and succinate were
increased in DOX-treated animals as compared to controls, which was correlated with nonen-
zymatic conversion of pyruvate to acetate and of α-ketoglutarate to succinate, as mediated by
DOX-induced free radicals.180 In fact, accumulation of acetate and succinate were proposed as
novel biomarkers for DOX cardiotoxicity.180 Also, myocardial levels of branched amino acids
(BCAAs) valine, leucine, and isoleucine are decreased, meaning that BCAAs can be used as an
energy reservoir, resulting from the fact that fatty acid β-oxidation is inhibited and Krebs cycle
is impaired (Fig. 4).180
The switch from long-chain fatty acid oxidation to alternative substrates is a common
feature of several stressful conditions, in which DOX cardiotoxicity is naturally included and
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Figure 4. Metabolic alterations described in DOX-induced cardiotoxicity. Cardiac metabolism is altered in
different levels by DOX. Besides the disruption of mitochondrial oxidative phosphorylation (OXPHOS), which
includes inhibition of Complex I activity, a number of other proteins involved in other metabolic pathways are
also affected. Mitochondrial CK isoenzymes (MtCK) are mandatory in the channeling of mitochondrial ATP to
creatine-phosphate, used as the source of energy in cardiomyocytes, AMPK activity is also inhibited by DOX,
which leads to a decline of fatty acid β-oxidation. AMPK downregulation negatively affects glucose transporters,
blocking the compensatory pathway that stimulates glucose uptake following disrupted OXPHOS. DOX, doxoru-
bicin; AMPK, adenosine monophosphate-activated protein kinase; OXPHOS, oxidative phosphorylation; GLUT1,
glucose transporter 1; NADH, nicotinamide adenine dinucleotide; CK, creatine kinase; PCr, phosphocreatine;
Cr, creatine; ATP, adenosine triphosphate; ADP, adenosine diphosphate.
may be an important contributor to the metabolic phenotype observed after DOX treatment,
resulting in persistent bioenergetic failure. One logical question is to know the extension of
the irreversibility of the metabolic injury/remodeling process and how that affects decreased
cardiac resistance to future deleterious stresses. However, very few data are available from
studies performed in humans, which is clearly a limitation. An important advancement in this
field would be a follow-up of global cardiac metabolism in former DOX patients as compared
with untreated subjects, not only during rested conditions but also when subjected to cardiac
stress (see below).
Studies involving maintenance of regular cardiac metabolism during DOX therapy by
using pharmacological strategies are also scarce with some exceptions. L-carnitine, which has
an important role in the import of long-chain fatty acids,181 has been tested aimedat normalizing
metabolism during DOX-induced cardiotoxicity. Results showed some success in decreasing
DOX cardiotoxicity in several experimental animal models.182,183 Interestingly, L-carnitine
supplementation reversed the decreased expression of the organic cation/carnitine transporter
in the cardiac muscle184 but did not normalize the activities of cardiac CPT-I.185 Despite this,
hyperlipidemia caused by DOX in rats was decreased by L-carnitine.34 The results appear to
suggest that L-carnitine may be operating in multiple levels and organs and that restoring long-
chain fatty acid oxidation may not be the primary mechanism by which L-carnitine operates.
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In fact, the antiapoptotic role of L-carnitine in a in vitro system of DOX toxicity was proposed
to originate from direct inhibition of a novel acid sphingomyelinase, which would lead to the
generation of ceramide and apoptosis.143 This particular aspect may be confusing since it is
known that inhibition of mitochondrial fatty acid β-oxidation at various levels may increase
the generation of toxic lipid metabolites, including ceramide, in the cardiomyocyte cytoplasm,
leading to cell death.186
Dexrazoxane reverted the metabolic consequences of DOX treatment in the heart, such
as inhibition of fatty acid β-oxidation and increased glycolytic rate. In this particular case, a
defect in the β-oxidationmechanism itself and not on fatty acid transport was found after DOX
treatment.177
Despite the lack of information from humans and from the degree of the reversibility of
metabolic alterations, it may be possible that metabolic depression, associated with subclinical
mitochondrial limitations, may contribute to decrease the susceptibility of the DOX-treated
heart to different types of stresses.
G. “Second-Hit” Stress in the DOX-Treated Hearts
Since a significant amount of DOX patients are pediatric, one important concern is whether
the treated myocardium will have the same behavior when subjected to different types of stress
later in life. Evidence from in vitro models, for example, isolated heart mitochondria from
DOX-treated rats, suggests that heart mitochondria from this experimental group are more
fragile in the presence of calcium and unable to increase respiration facing a demand of ATP,
mimicked in vitro by the addition of ADP.89 This suggests that DOX toxicity may remain silent
and thus undetectable under unstressed situations, but may become visible and a matter of
concern when the myocardium is forced to perform stressful work. In fact, the literature is
scarce when exploring this subject, that is, there is not a lot of research available on how DOX
primes the myocardium to respond differently to different types of stress.
Pregnancy has been considered a potential risk condition for patients that have been
previously treated with DOX for childhood cancers. The literature available appears to suggest
that pregnanciesmayhave a favorable, complication-free outcome if basal ventricular function is
normal before pregnancy. On the other hand, there are risks for the pregnancy if left ventricular
function during rest is already deteriorated.187 Several peripartum cardiomyopathy and heart
failure clinical cases have been described so far,188,189 which again shows that patients that were
previously treated with DOX in an early age should be followed very closely in the event of a
pregnancy. Also, one important point of concern is the fact that offspring fromDOX childhood
patients may present birth defects or higher cancer incidence. Nevertheless, one available study
performed in 405 former childhood cancer survivors, showed no increased rate for any of those
end points.190
Despite the fact that exercise can prove very beneficial against DOX-induced cardiotoxicity
if performed before the treatment191 (see below), it can also be a source of metabolic overload
for an already stressed cardiac muscle. One interesting and recent paper demonstrated that
voluntary exercise in young rats, initiated whenDOX treatment was started, was able to prevent
the persistence of DOX chronic toxicity.192 Data from patients suggest that at least during the
initial three decades of life, exercise is not detrimental to the cardiac function in childhood
cancer survivors. Black et al.193 demonstrated that in most of 56 patients aged 9–28 years, 44
patients of which had been treated with 15–483 mg/m2 DOX, no signs of cardiac alterations
were observed during a physical activity protocol. Despite these promising studies, there are
voids in the actual knowledge, one being the exercise capacity of older survivors of DOX-
treated childhood cancer. The other important aspect, and clearly related to the main topic of
the present review, is to question whether the bioenergetic deficit and accompanying metabolic
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remodeling in DOX-treated patients is irreversible and whether these bioenergetic deficits can
impact the resistance of the myocardium to “second-hit” stresses, not only including exercise
and pregnancy, but also the cardiovascular burden posed by obesity, diabetes, or a lifestyle of
increased emotional stress. These topics are still mostly open for investigation.
H. Delayed DOX Toxicity: Can we Stop Something under the Surface?
As widely described in the previous sections, one particular aspect of DOX toxicity is a de-
layed component, surfacing years or even decades after treatment.194 Despite all the knowledge
gathered along the last decades, we are still far from identifying the mechanism(s) behind
the delayed cardiac toxicity. It is doubtful that traces of DOX may remain in the cardiac
tissue years after cessation of the treatment, despite the fact that DOX may bind to mitochon-
drial cardiolipin.66,67 Proposed mechanisms to explain delayed DOX cardiotoxicity range from
progressive impairment of sarcoplasmic reticulum calcium-handling mechanisms, which was
observed 13 and 18 weeks after the termination of treatment195 to free radical-derived DNA
lesions.196 One should be aware that DOX-induced oxidative lesions on mtDNA100,101 can also
contribute to a progressive decay of mitochondrial capacity, which will cease to be subclinical
after a certain threshold is crossed. Another possible explanation may involve the selective
removal of progenitor cells in young patients,28 which will later limit the already restricted
regenerative capacity of the heart.
Different therapies have been proposed facing data from animal models. These range
from antioxidants such as coenzyme Q10,197 calcium antagonists such as flunarizine198 or
metabolic/antioxidant agents such as trimetazidine.199 But again, data in humans are still
scarce regarding approaches to prevent DOX delayed toxicity. Also, would it be correct to
treat a former cancer patient that received DOX with a myriad of protective compounds, not
knowing the impact of this supposedly “protective” therapy in normal cardiac physiology? The
fact that DOX cardiotoxicity may remain silent for decades does not motivate the cardiolo-
gist or the general practitioner into prescribing drugs for something that may not exist. One
possible solution may be physical activity, which has been described to decrease DOX toxicity.
The next section will provide positive arguments for the use of regular exercise in improving
metabolism and especially mitochondrial capacity in the hearts of former DOX patients. Data
exist showing the exercise is effective in counteracting acute and subchronicDOXcardiotoxicity.
If demonstrated, a protective role against delayed DOX toxicity will not come as a surprise.
3. BOOSTING CARDIAC MITOCHONDRIAL CAPACITY AND DEFENSES WITH
PHYSICAL ACTIVITY: LIMITING THE DAMAGE
The beneficial effects of exercise in the cardiac muscle are widely reported, and include up-
regulation of heart antioxidant systems,200 improvement of mitochondrial function, reduction
of the formation of lipid peroxidation by-products,201 and induction of heat shock proteins
(HSPs) overexpression.202 Without surprise, exercise affords cross-tolerance against a series of
cardiac pathologies and stresses, including diabetes.203 It is important to note that exercise can
positively modulate some important cardiac defense systems to antagonize the toxic effects
caused by DOX treatment.191 Exercise can present different types of schedules and intensities,
including acute treadmill running, short- or long-term forced endurance training in the form
of treadmill running or swimming as well as voluntary physical activity, resulting in different
physical responses and mechanical stresses.191,204
In fact, a single endurance exercise bout can preserve cardiac function and protect the
heart against cardiac dysfunction, oxidative stress, and lipid peroxidation.205–209 Wonder
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et al.205 reported that an acute exercise bout performed 24 hr before DOX treatment pro-
tected against cardiac dysfunction. Also, exercise-induced cardioprotection could partly be
explained by a reduction in the generation of ROS; however, the mitochondrial mechanisms
responsible for this cardioprotection against DOX effects remained vague.205 Ascensa˜o and
co-workers51 determined the effects of an acute exercise bout on heart mitochondrial function
before DOX administration. Exercise prevented most of the deleterious mitochondrial alter-
ations caused by DOX treatment, including the decrease in heart mitochondrial function and
increased calcium-induced MPT, besides increasing cardiac mitochondrial SOD activity and
preventing apoptotic signaling. Clearly, this study supports that acute exercise protects against
cardiac mitochondrial dysfunction. However, due to the high rates of oxygen consumption and
ROS production in acute exercise and to the low cardiac muscle ability to neutralize ROS, acute
exercise should be recommended only under controlled circumstances, especially for patients
with a previous history of heart disease.210,211
Endurance training can be defined as the repeated act of exercising to increase aerobic
fitness. Long-term endurance training induces many physiological adaptations, which have
been described to counteract several pathologies.212,213 Regular exercise is known to upregu-
late cardiac antioxidant systems and to support greater tolerance in the myocardium, with a
resulting broad enhancement in its function, both at rest and when subjected to oxidative stress
stimuli.211 Ascensa˜o et al.41,204 demonstrated that endurance exercise, prior to DOX treatment,
protected the hearts of rats and mice against DOX cardiotoxicity. Also, training prevented the
induction of the MPT pore by decreasing the sensitivity to calcium observed in nontrained
DOX-treated rats.41,204 Moreover, training inhibited a DOX-induced increase in mitochondrial
protein carbonyl groups and lipid peroxidation,214 and Bax, Bax/Bcl-2 ratio, induction of
MPT pore and tissue caspase-3 activity.41 Contributing to the protective phenotype, endurance
training increased GSH, mitochondrial HSP-60, whole tissue HSP-70,214 and mitochondrial
and cytosolic forms of SOD.41,204 All of these effects resulting from endurance training were
able to protect and improve heart mitochondrial respiratory function from the toxic effects of
DOX, probably by improving mitochondrial and cell defense systems and reducing cell oxida-
tive stress. All of these modifications at the cellular and ultrastructural levels are reflected in
an improvement of cardiac functional parameters. For instance, endurance training prevented
DOX-induced decrease in heart rate, left ventricular developed pressure and dP/dtmax.214
Regrettably, there is a shortage of basic scientific works demonstrating the impact of the
diverse forms of exercise in cardiac metabolism, including fatty acid β-oxidation and glycolytic
rates. The promising results obtained with exercise in the context of DOX cardiotoxicity would
warrant such an approach. Nevertheless, a word of caution must be said. One size does not
fit all. Patients should be carefully seen by a cardiologist before starting an endurance training
protocol and during several time points. Our limited knowledge of themechanisms that exercise
activates to afford cell protection, combined with the unknown involvingDOXdelayed toxicity,
inhibits the use of physical activity to prevent the latter before further studies.
Interestingly, caloric restriction may resemble the positive effects of exercise. Chen et al.215
demonstrated that caloric restriction induced by the nonmetabolized mimetic 2-deoxyglucose
(2-DG) antagonizedDOX-induced rat neonatal cardiomyocyte death. 2-DGdecreased intracel-
lular ATP levels by about 20% but prevented the large deficit of ATP following DOX treatment.
Moderate caloric restriction was also demonstrated to be effective by rendering the heart more
resistant to DOX toxicity in a rodent model.216 The effect was not dependent on differential ac-
cumulation of DOX in the heart but on multiple pathways, including activation of JAK/STAT
signaling, decreased oxidative stress, or higher ATP/ADP ratio. Fatty acid oxidation in the
myocardium was also increased in this model of moderately restricted diet, which may present
a positive impact as well. Kawaguchi et al. elegantly demonstrated that increasing cardiac
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Figure 5. Doxorubicin (DOX): from molecular events to cardiomyopathy. The present figure exemplifies the
complexity of the progression of DOX cardiotoxicity from acute events to the still badly understood delayed
toxicity, which involves the development of congestive heart failure. The figure extends the schematics shown
in the previous figures to a temporal scale. We also propose that DOX causes, not only, macromolecular oxida-
tive damage (ROS), which damages proteins, membranes, and genetic material, but also alters permanently
the redox balance in different compartments (“ros,” e.g., mitochondria, nucleus, and sarcoplasmic reticulum).
Disturbances in the equilibrium of redox pairs GSH/GSSG and cystein/cystine can compromise enzyme activity
and several metabolic processes, which can later result in macromolecular oxidative stress. The figure also
shows two possible moments when apoptotic signaling may increase. The first occurs after the initial stages
of treatment and may affect cardiomyoctes and/or progenitor cells, while a second bout of apoptotic signaling
may occur later, when cardiomyocyte metabolic and genetic errors trigger several death pathways. There is
not a defined time frame of when the different events occur. What should be clear is that we propose several
redundant pathways for cellular damage, which limits the efficacy of protective agents.
autophagy by prior starvation decreases acute DOX cardiotoxicity, suggesting a protective role
of cardiac autophagy in removing damaged structures after DOX treatment.217 The protective
role of caloric restriction may thus be due, at least in part, by increasing autophagic fluxes in
the cardiac tissue.
4. GRAND FINALE AND A LIMITING PROBLEM IN ANIMAL STUDIES
DOX cardiotoxicity remains a huge challenge in oncology. Since DOX causes a progressive
deterioration of mitochondrial metabolism, this can serve as a basis not only for the phenotype
observed in DOX-treated animal models and humans but also for the metabolic remodeling
that results from DOX treatment and whose consequences for long-term DOX therapy are
still largely unknown. The multifactorial nature of DOX effects and the domino effect that
each molecular event may trigger (Fig. 5), can explain why protective agents that otherwise
are promising on paper, fail to provide the expected protection. It is also important to note
that some of the observed cardiovascular effects may also be consequence of DOX toxic-
ity on other organs, including the kidneys,218 which although milder than in the heart and
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affecting a lower number of patients, can further complicate the picture and the efficacy of
many cytoprotectants.
Also, basic research should be focused on how cell and mitochondrial metabolism are
maintained in an altered state and what are the consequences of that for a later life cardiac
failure or decreased resistance to “second-hit” stressful events. It also appears logical that mito-
chondria appear in the first line for protection by pharmacological and nonpharmacological ap-
proaches in order to further preventmetabolic remodeling thatmay prove deleterious in the long
term.
One critical problem with several of the animal studies aimed at understanding the mecha-
nisms behindDOX toxicity is the choice of healthy animals in the vast majority of studies.Most
studies, including our own, investigate the cardiotoxicity of DOX in animal models devoid of
tumors. This extra physiological burden may alter the cardiac effects of DOX, with the ad-
vantage of studying the effects of different compounds on cardiac tissue and in modulation of
DOX anticancer efficacy. In a model bearing more resemblance to the clinical reality, Todorova
et al.219,220 observed that oral glutamine administration was able to reduce oxidative damage
in the heart of tumor-bearing rats. This study is important for two main reasons. One is the
evidence that oral glutamine is able to decrease oxidative damage caused by DOX in the heart
but not in the tumor. The second important reason has, of course, to do with the model itself.
The authors chose to use an animal model that harbors a tumor. Despite this, this is a step
forward in improving the biological model, the truth still is that a rat (or mouse) is different
from a human, which justifies that protective agents that work in animal models fail to do so in
humans.221 Finally, a critical feature of DOX cardiotoxicity is its persistent and delayed nature.
With the exception of a few studies,48,71,103,222 a need exists for proper models for DOX delayed
cardiotoxicity.
In conclusion, much is yet to be done and further research will continuously be con-
ducted in an attempt to validate the essential mechanisms responsible for DOX toxicity and
metabolic/mitochondrial alterations involved therein and to develop new therapeutic strategies
to prevent premature cardiomyocyte death in cancer patients that benefit from anthracycline
treatment. This is an even bigger challenge for childhood cancer survivors.
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